Trial Outcomes & Findings for Effects of Heart Rate Oscillations During Meditation on Plasma Biomarkers of Alzheimer's Disease (NCT NCT06210035)

NCT ID: NCT06210035

Last Updated: 2026-01-05

Results Overview

The investigators computed an aggregate Z-score based on plasma Aβ40 and Aβ42 levels (pg/mL). A Z-score of 0 represents the sample mean. Higher values indicate a greater level of plasma Aβ, which in cognitively normal individuals has been found to be associated with a higher risk of converting to Alzheimer's disease (Song et al., 2011). They conducted a 2 (time: pre, post) × 3 (condition) ANOVA to test for a time × condition interaction in plasma Aβ levels, assessing group differences in change over time.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

94 participants

Primary outcome timeframe

Measured from blood draws before and after a one-week intervention

Results posted on

2026-01-05

Participant Flow

Out of the 94 participants enrolled, 2 dropped before condition assignment.

Participant milestones

Participant milestones
Measure
Belly-focus Concentration Meditation
Participants will engage in concentration meditation for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly. Belly-focus meditation: Participants will engage in concentration meditation for 40 minutes every day for a week. They will focus on the sensations around the belly.
Belly-focus Concentration Meditation With Slow Breathing
Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly while breathing slowly. Belly-focus meditation with slow breathing: Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week. They will focus on the sensations around the belly while breathing slowly.
No-intervention Control
Participants will rest quietly for 40 minutes every day for a week while recording heart rate.
Overall Study
STARTED
30
32
30
Overall Study
COMPLETED
27
32
30
Overall Study
NOT COMPLETED
3
0
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Belly-focus Concentration Meditation
Participants will engage in concentration meditation for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly. Belly-focus meditation: Participants will engage in concentration meditation for 40 minutes every day for a week. They will focus on the sensations around the belly.
Belly-focus Concentration Meditation With Slow Breathing
Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly while breathing slowly. Belly-focus meditation with slow breathing: Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week. They will focus on the sensations around the belly while breathing slowly.
No-intervention Control
Participants will rest quietly for 40 minutes every day for a week while recording heart rate.
Overall Study
Withdrawal by Subject
3
0
0

Baseline Characteristics

Effects of Heart Rate Oscillations During Meditation on Plasma Biomarkers of Alzheimer's Disease

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Belly-focus Concentration Meditation
n=30 Participants
Participants will engage in concentration meditation for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly. Belly-focus meditation: Participants will engage in concentration meditation for 40 minutes every day for a week. They will focus on the sensations around the belly.
Belly-focus Concentration Meditation With Slow Breathing
n=32 Participants
Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly while breathing slowly. Belly-focus meditation with slow breathing: Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week. They will focus on the sensations around the belly while breathing slowly.
No-intervention Control
n=30 Participants
Participants will rest quietly for 40 minutes every day for a week while recording heart rate.
Total
n=92 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=9667 Participants
0 Participants
n=6597 Participants
0 Participants
n=16264 Participants
0 Participants
n=31 Participants
Age, Categorical
Between 18 and 65 years
30 Participants
n=9667 Participants
32 Participants
n=6597 Participants
30 Participants
n=16264 Participants
92 Participants
n=31 Participants
Age, Categorical
>=65 years
0 Participants
n=9667 Participants
0 Participants
n=6597 Participants
0 Participants
n=16264 Participants
0 Participants
n=31 Participants
Age, Continuous
25.07 years
STANDARD_DEVIATION 5.16 • n=9667 Participants
26.25 years
STANDARD_DEVIATION 5.29 • n=6597 Participants
26.20 years
STANDARD_DEVIATION 4.82 • n=16264 Participants
25.73 years
STANDARD_DEVIATION 5.05 • n=31 Participants
Sex: Female, Male
Female
24 Participants
n=9667 Participants
26 Participants
n=6597 Participants
25 Participants
n=16264 Participants
75 Participants
n=31 Participants
Sex: Female, Male
Male
6 Participants
n=9667 Participants
6 Participants
n=6597 Participants
5 Participants
n=16264 Participants
17 Participants
n=31 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants
n=9667 Participants
13 Participants
n=6597 Participants
8 Participants
n=16264 Participants
24 Participants
n=31 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
25 Participants
n=9667 Participants
18 Participants
n=6597 Participants
22 Participants
n=16264 Participants
65 Participants
n=31 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
2 Participants
n=9667 Participants
1 Participants
n=6597 Participants
0 Participants
n=16264 Participants
3 Participants
n=31 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=9667 Participants
1 Participants
n=6597 Participants
0 Participants
n=16264 Participants
1 Participants
n=31 Participants
Race (NIH/OMB)
Asian
13 Participants
n=9667 Participants
9 Participants
n=6597 Participants
10 Participants
n=16264 Participants
32 Participants
n=31 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=9667 Participants
0 Participants
n=6597 Participants
0 Participants
n=16264 Participants
0 Participants
n=31 Participants
Race (NIH/OMB)
Black or African American
6 Participants
n=9667 Participants
3 Participants
n=6597 Participants
0 Participants
n=16264 Participants
9 Participants
n=31 Participants
Race (NIH/OMB)
White
9 Participants
n=9667 Participants
8 Participants
n=6597 Participants
10 Participants
n=16264 Participants
27 Participants
n=31 Participants
Race (NIH/OMB)
More than one race
2 Participants
n=9667 Participants
3 Participants
n=6597 Participants
4 Participants
n=16264 Participants
9 Participants
n=31 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=9667 Participants
8 Participants
n=6597 Participants
6 Participants
n=16264 Participants
14 Participants
n=31 Participants
Region of Enrollment
United States
30 participants
n=9667 Participants
32 participants
n=6597 Participants
30 participants
n=16264 Participants
92 participants
n=31 Participants

PRIMARY outcome

Timeframe: Measured from blood draws before and after a one-week intervention

Population: Population analyzed is composed by all randomization subjects who completed pre- and post-intervention blood draw and whose data quality was sufficient for data analysis.

The investigators computed an aggregate Z-score based on plasma Aβ40 and Aβ42 levels (pg/mL). A Z-score of 0 represents the sample mean. Higher values indicate a greater level of plasma Aβ, which in cognitively normal individuals has been found to be associated with a higher risk of converting to Alzheimer's disease (Song et al., 2011). They conducted a 2 (time: pre, post) × 3 (condition) ANOVA to test for a time × condition interaction in plasma Aβ levels, assessing group differences in change over time.

Outcome measures

Outcome measures
Measure
Belly-focus concentration meditation
n=24 Participants
Participants will engage in concentration meditation for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly. Belly-focus meditation: Participants will engage in concentration meditation for 40 minutes every day for a week. They will focus on the sensations around the belly.
Belly-focus concentration meditation with slow breathing
n=28 Participants
Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly while breathing slowly. Belly-focus meditation with slow breathing: Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week. They will focus on the sensations around the belly while breathing slowly.
No-intervention control
n=26 Participants
Participants will rest quietly for 40 minutes every day for a week while recording heart rate.
Change in Plasma Amyloid Beta (Aβ) Levels
pre
-0.38 Z-score
Standard Error 0.19
0.02 Z-score
Standard Error 0.17
0.24 Z-score
Standard Error 0.18
Change in Plasma Amyloid Beta (Aβ) Levels
post
-0.08 Z-score
Standard Error 0.17
-0.29 Z-score
Standard Error 0.16
0.22 Z-score
Standard Error 0.16

PRIMARY outcome

Timeframe: Measured from blood draws before and after a one-week intervention

Population: Population analyzed is composed by all randomization subjects who completed pre- and post-intervention blood draw and whose data quality was sufficient for data analysis.

The investigators conducted a 2 (time: pre, post) × 3 (condition) ANOVA to test for an interaction effect on plasma Ab42/40 ratios. The plasma Ab42/40 ratio was calculated by dividing the plasma Ab42 concentration (pg/ml) by the plasma Ab40 concentration (pg/ml). A higher plasma Ab42/40 ratio indicates better outcome (i.e., greater brain clearance).

Outcome measures

Outcome measures
Measure
Belly-focus concentration meditation
n=22 Participants
Participants will engage in concentration meditation for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly. Belly-focus meditation: Participants will engage in concentration meditation for 40 minutes every day for a week. They will focus on the sensations around the belly.
Belly-focus concentration meditation with slow breathing
n=28 Participants
Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly while breathing slowly. Belly-focus meditation with slow breathing: Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week. They will focus on the sensations around the belly while breathing slowly.
No-intervention control
n=25 Participants
Participants will rest quietly for 40 minutes every day for a week while recording heart rate.
Change in Plasma Ab42/40 Ratio
pre
0.05 ratio of Aβ42 to Aβ40
Standard Error 0.002
0.05 ratio of Aβ42 to Aβ40
Standard Error 0.001
0.05 ratio of Aβ42 to Aβ40
Standard Error 0.001
Change in Plasma Ab42/40 Ratio
post
0.05 ratio of Aβ42 to Aβ40
Standard Error 0.002
0.05 ratio of Aβ42 to Aβ40
Standard Error 0.001
0.05 ratio of Aβ42 to Aβ40
Standard Error 0.002

SECONDARY outcome

Timeframe: Measured from blood draws before and after a one-week intervention

Population: Population analyzed is composed by all randomization subjects who completed pre- and post-intervention blood draw and whose data quality was sufficient for data analysis.

The investigators conducted a 2 (time: pre, post) × 3 (condition) ANOVA to test for an interaction effect on plasma pTau-181/total Tau ratios. The plasma pTau-181/total Tau ratio was calculated by dividing the plasma pTau-181 concentration (pg/ml) by the plasma total Tau concentration (pg/ml). A higher plasma pTau-181/total Tau ratio indicates better outcome (i.e., greater brain clearance).

Outcome measures

Outcome measures
Measure
Belly-focus concentration meditation
n=23 Participants
Participants will engage in concentration meditation for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly. Belly-focus meditation: Participants will engage in concentration meditation for 40 minutes every day for a week. They will focus on the sensations around the belly.
Belly-focus concentration meditation with slow breathing
n=25 Participants
Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly while breathing slowly. Belly-focus meditation with slow breathing: Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week. They will focus on the sensations around the belly while breathing slowly.
No-intervention control
n=23 Participants
Participants will rest quietly for 40 minutes every day for a week while recording heart rate.
Change in Plasma pTau-181/Tau Ratio
pre
5.30 ratio of pTau-181 to total Tau
Standard Error 0.38
4.78 ratio of pTau-181 to total Tau
Standard Error 0.37
5.02 ratio of pTau-181 to total Tau
Standard Error 0.38
Change in Plasma pTau-181/Tau Ratio
post
4.73 ratio of pTau-181 to total Tau
Standard Error 0.37
5.29 ratio of pTau-181 to total Tau
Standard Error 0.36
4.64 ratio of pTau-181 to total Tau
Standard Error 0.37

SECONDARY outcome

Timeframe: Measured before and after a one-week intervention

Population: Population analyzed is composed by all randomization subjects who completed the emotional well-being survey (i.e., POMS) at pre- and post-intervention and whose data quality was sufficient for data analysis.

The investigators conducted a 2 (time: pre, post) × 3 (condition) ANOVA to test for an interaction effect on emotional well-being. Emotional well-being was assessed using the Profile of Mood States (POMS), which consists of 40 items rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). Total Mood Disturbance (TMD) scores were calculated by summing the negative mood items and subtracting the sum of the positive mood items. A constant of 100 was added to the TMD score to eliminate negative values. Higher scores indicate more negative mood states, with possible scores ranging from 56 to 216.

Outcome measures

Outcome measures
Measure
Belly-focus concentration meditation
n=27 Participants
Participants will engage in concentration meditation for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly. Belly-focus meditation: Participants will engage in concentration meditation for 40 minutes every day for a week. They will focus on the sensations around the belly.
Belly-focus concentration meditation with slow breathing
n=31 Participants
Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly while breathing slowly. Belly-focus meditation with slow breathing: Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week. They will focus on the sensations around the belly while breathing slowly.
No-intervention control
n=26 Participants
Participants will rest quietly for 40 minutes every day for a week while recording heart rate.
Change in Emotional Well-being
pre
87.15 score on a scale
Standard Error 2.29
87.39 score on a scale
Standard Error 2.14
94.73 score on a scale
Standard Error 2.34
Change in Emotional Well-being
post
89.89 score on a scale
Standard Error 2.93
84.68 score on a scale
Standard Error 2.73
94.96 score on a scale
Standard Error 2.99

OTHER_PRE_SPECIFIED outcome

Timeframe: Measured after a one-week intervention

The investigators will conduct a one-way ANOVA to assess group differences in episodic memory.

Outcome measures

Outcome data not reported

Adverse Events

Belly-focus Concentration Meditation

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

Belly-focus Concentration Meditation With Slow Breathing

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

No-intervention Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Belly-focus Concentration Meditation
n=30 participants at risk
Participants will engage in concentration meditation for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly. Belly-focus meditation: Participants will engage in concentration meditation for 40 minutes every day for a week. They will focus on the sensations around the belly.
Belly-focus Concentration Meditation With Slow Breathing
n=32 participants at risk
Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly while breathing slowly. Belly-focus meditation with slow breathing: Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week. They will focus on the sensations around the belly while breathing slowly.
No-intervention Control
n=30 participants at risk
Participants will rest quietly for 40 minutes every day for a week while recording heart rate.
Blood and lymphatic system disorders
Adverse events after blood draw
10.0%
3/30 • One week
0.00%
0/32 • One week
0.00%
0/30 • One week

Additional Information

Dr. Mara Mather

University of Southern California

Phone: (213) 821-1868

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place